Thematic (Sector/Industry)

US equities mixed: Dow +0.5%, S&P 500 +0.1%, Nasdaq -0.6% as technology selling continued.
July Flash PMI expanded at the fastest pace in eight months, helping offset the impact of new 10–12.5% Section 301 tariffs.
Brent crude fell 4% on Friday but still finished the week up 11% on ongoing Middle East tensions.

China Strategy: Evolution of H-Share IPO Premium/Discount

By Osbert Tang, CFA

Since 2025, there have been 48 H-share IPOs of listed A-shares, with most seeing HA discounts widen post-listing, with only 20 narrowing.
Only AI-related H-share IPOs achieved meaningful HA discount narrowing (over 10pp), with non-AI names failing since May 2025.
The market capitalisation of these IPOs is not decisive for the HA discount change, and the overall market effect has little impact. Hence, the AI theme remains the key.

Japan Morning Connection: Risk-On Mood May Return as Red Sea Tensions Ease

Kokusai Elec and Micronics may see upside as CXMT’s blockbuster IPO nears, with its retail tranche reportedly 212x oversubscribed.
TDK, Minebea Misumi and Nitto Denko may face pressure after Qualcomm’s price hike points to lower sales of cheaper handsets across Asia.
Ibiden and TEL look unfairly sold on Friday and worth revisiting today.

China Healthcare Weekly Wrap (20-24 July)

By Wilfred Yuen

Akeso-Partner Summit Therapeutics released 2Q26 results. See our takeaways published earlier Akeso (9926.HK): SMMT 2Q26 Call Takeaways on Ivonescimab
Harbour Bio, MicroPort MedBot, and Shanghai HeartCare released positive profit alerts; Wuxi Bio reached 10,000 molecules milestone; Ribo Life released positive Europe phase 2a study in its siRNA FXI inhibitor
China’s NMPA become the first approved Takeda’s orexin narcolepsy drug; Science and Retraction Watch reported a girl death from a brain base-editing trial in Shanghai

SEMICONDUCTOR MEMORY CYCLE MONITOR — Issue #3 | 18–25 July 2026

By Mo Aziz

Mixed Recovery: US memory names bounced 6–9% (Micron, SanDisk) while Korean names barely moved. Forced liquidation is still clearing. Alphabet’s USD200bn capex hike validates the AI memory thesis.
SK Hynix Q2 results on 29 July — consensus KRW84T revenue, KRW64T operating profit, ~75–77% margin — is the week’s defining event. First print as a Nasdaq-listed company.
Long SK Hynix (000660 KS / SKHY US) open: entry KRW1,842,000, current KRW1,759,000. CXMT (688825 CH) debuts on STAR Market Monday — Asia’s largest IPO of 2026.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 26

0

Daily Brief Thematic (Sector/Industry): Japan Strategy Weekly | Bifurcation Season and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Japan Strategy Weekly | Bifurcation Season
APAC Healthcare Weekly (July 26) – Hengrui, BeOne, Takeda, Nippon Shinyaku, Samsung Bio, Celltrion

Japan Strategy Weekly | Bifurcation Season

Earnings season may accelerate the rotation from AI momentum into quality compounders with earnings visibility.
Macro headwinds with oil above $100, yen at 40-year lows, BOJ tightening on the horizon
We expect this dynamic to persist through August reporting season.

APAC Healthcare Weekly (July 26) – Hengrui, BeOne, Takeda, Nippon Shinyaku, Samsung Bio, Celltrion

By Tina Banerjee

Jiangsu Hengrui received NMPA approval for camrelizumab as a first-line treatment of recurrent or metastatic cervical cancer. BeOne Medicines announced $300M expansion of its New Jersey manufacturing and R&D center.
Takeda Pharmaceutical got China approval for Orzeyful as a treatment of narcolepsy type 1. Nippon Shinyaku outlicences NS-025 to Aquelys Therapeutics for the treatment of xerostomia associated with Sjögren’s disease.
Samsung Biologics is acquiring PolyPeptide, a leading global CDMO specializing in peptide-based API, for CHF1.46B. Celltrion has applied to the EMA for marketing authorization for its Cosentyx biosimilar candidate, CT-P55.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 25

0

Daily Brief Thematic (Sector/Industry): Tencent/Netease: One Game for NetEase as July Approvals Hit New High and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Tencent/Netease: One Game for NetEase as July Approvals Hit New High
Singapore Market Roundup (24-Jul-2026): DBS Views M. Deal as Vital for SGX Growth and Earnings.
India’s Cancer Care Opportunity: Listed Proxies for a 1.6 Million-Case Market
AUCTUS ON FRIDAY – 24.07.2026
Energy Roundup : US LNG Export Success
Domestic Lithium Developer Takes Center Stage as Policy, AI, and Energy Demand Converge
Asia Real Estate Tracker (24-Jul-2026): GLP sells Shanghai hotel to Shanda for $32M.

Tencent/Netease: One Game for NetEase as July Approvals Hit New High

By Ke Yan, CFA, FRM

China announced game approval for the July batch. The number of games approved remained at a higher level than in 2023 and 2024.
The pace of China game approval appears to have accelerated to the same level as pre-tightening.
Of the companies that we are monitoring, Netease got 1 approval.

Singapore Market Roundup (24-Jul-2026): DBS Views M. Deal as Vital for SGX Growth and Earnings.

DBS sees M. deal as key to SGX’s growth and potential earnings boost.
RHB maintains ‘buy’ on CSE Global after US$8 million SEI acquisition.
World Cup impacts high-value gaming patrons; DBS retains ‘hold’ on Genting Singapore.

India’s Cancer Care Opportunity: Listed Proxies for a 1.6 Million-Case Market

By Nimish Maheshwari

India recorded an estimated 1.56 million new cancer cases and 0.90 million deaths in 2024. The long-duration demand curve points toward materially higher case volumes by 2040–50.
The listed opportunity is concentrated in oncology capacity, radiotherapy, surgery, diagnostics and accessible drugs. These are scalable revenue pools today, not distant optionality.
HCG Offers the highest cancer purity; Max and Apollo combine oncology with network strength; Medanta adds capacity optionality. Biocon, Dr. Reddy’s and Metropolis are indirect enablers.

AUCTUS ON FRIDAY – 24.07.2026

By Auctus Advisors

AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; Target price of A$0.16 per share: Equity raise to fund Production growth and exploration upside in Austria – ADX has raised A$3.58 mm in new equity at A$0.020 per share.
Investors also received one option per new share, exercisable at A$0.030 per share.
Proceeds will fund the extended testing programme at the HOCH‑1 shallow gas discovery, ongoing shallow gas drilling at GOLD-1, Sicily Channel prospect maturation and working capital.

Energy Roundup : US LNG Export Success

By Water Tower Research

US providing majority of global LNG growth.
Per the Energy Institute’s Statistical Review of World Energy 2026 released earlier this month, the US generated 92% of the world’s growth in liquefied natural gas (LNG) exports last year.
In total, global LNG exports grew by nearly 1.2 trillion cubic feet in 2025, with the US supplying ~1.1 trillion cubic feet of that increase.

Domestic Lithium Developer Takes Center Stage as Policy, AI, and Energy Demand Converge

By Water Tower Research

Positioning for a larger audience. Management believes the proposed NASDAQ listing represents more than a change in trading venue, it is intended to place McDermitt in front of a much broader universe of US institutional investors, strategic partners, and government-backed financing programs as the project advances toward feasibility.
The transaction also creates a dedicated development platform with the flexibility to pursue future project funding independently of its Australian parent.
Structural tailwinds gaining momentum. The investment case for domestic lithium continues to strengthen as battery energy storage systems, AI-driven electricity demand, and grid modernization create new sources of long-term lithium consumption.

Asia Real Estate Tracker (24-Jul-2026): GLP sells Shanghai hotel to Shanda for $32M.

GLP has sold a hotel in Shanghai to Shanda for $32 million, indicating active real estate transactions.
Vita Partners, with backing from Warburg, has acquired Stockland’s Sydney Life Science Campus recently.
JD has purchased a building in West London for $197 million to establish its new UK headquarters.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 24

0

Daily Brief Thematic (Sector/Industry): Japan Morning Connection: Intel’s Big Beat and Capex Guidance Raise Set to Lift JP Suppliers and SPE and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Japan Morning Connection: Intel’s Big Beat and Capex Guidance Raise Set to Lift JP Suppliers and SPE
The Agentic Age #01
Asia Real Estate Tracker (23-Jul-2026): JD acquires £197M HQ in West London.
Singapore Market Roundup (23-Jul-2026): DBS maintains ‘hold’ on Genting Singapore due to World

Japan Morning Connection: Intel’s Big Beat and Capex Guidance Raise Set to Lift JP Suppliers and SPE

Lasertec, TEL, Screen and TOK to benefit from Intel’s strong earnings.
Disco’s guidance miss may present a chance to buy the dip.
Power-Semi’s may be under the pump after STMicro tanked -17.7% in EU and -18.7% in US trading from earnings disappointment.

The Agentic Age #01

By Animoca Brands Research

Frontier intelligence converged; price didn’t.
Claude Fable 5 (Intelligence Index 60) and GPT-5.6 Sol (59) sit one point apart at roughly a 3x cost spread per task.
Five models from three labs now cluster within six points at the top of the leaderboard.

Asia Real Estate Tracker (23-Jul-2026): JD acquires £197M HQ in West London.

JD has made a significant investment by acquiring a £197 million property in West London for its new UK headquarters.
Hong Kong’s ITC is set to develop a 1GW data center campus in Jiangsu, focusing on enhancing digital transformation efforts.
Link REIT has divested a 50% stake in Sydney’s 100 Market Street for $158 million, while SC Capital bought a luxury compound in Hong Kong for $39 million.

Singapore Market Roundup (23-Jul-2026): DBS maintains ‘hold’ on Genting Singapore due to World

DBS keeps ‘hold’ on Genting Singapore, citing World Cup’s impact on gaming patrons.
CGS International raises Yangzijiang Shipbuilding’s target price to $5.10.
RHB optimistic on CLAR; portfolio changes expected to boost DPU from FY2027.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 23

0

Daily Brief Thematic (Sector/Industry): Data Centres: The Asset Class Powering the Digital Economy and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Data Centres: The Asset Class Powering the Digital Economy
Japan Morning Connection: Intel Supply Chain in Focus as SK Hynix Eyed for Ohio Campus Role
Asia Real Estate Tracker (22-Jul-2026): Link REIT sells 50% of 100 Market St, Sydney, for $158M.
Singapore Market Roundup (22-Jul-2026): CGS International boosts Yangzijiang target price to

Data Centres: The Asset Class Powering the Digital Economy

By Garreth Elston

Power is the product. Data centres are sold by the megawatt, not the square metre. Whoever secures the electricity controls the value.
The usual property metrics mislead. Cap rates and occupancy metrics, borrowed from real estate, hide the huge mandatory upgrade cycles these assets demand. Standard valuation reaches the wrong answer.
Governments now decide. Grid access and planning approval, not customer demand, determine which projects get built. Regulators in Singapore, Ireland and US states have become the real gatekeepers of supply.

Japan Morning Connection: Intel Supply Chain in Focus as SK Hynix Eyed for Ohio Campus Role

Alphabet revealed plans to spend aggressively on AI computing capacity, a positive for semi-caps and Japan’s SPE firms.
A mild negative for Harmonic Drive after Musk flagged that scaling Optimus production will be tough to scale.
News that SK Hynix is being considered as a partner to run Intel’s Ohio campus is a positive for SPE names in Intel’s supply chain and memory-related names.

Asia Real Estate Tracker (22-Jul-2026): Link REIT sells 50% of 100 Market St, Sydney, for $158M.

Link REIT has divested a 50% stake in Sydney’s 100 Market Street for $158 million to Aware Super.
Kingsford’s acquisition of a redevelopment site in Singapore for $736 million is the year’s largest sale.
A Frasers-led consortium has purchased a mixed-use site in Singapore’s Bayshore area for $1.65 billion.

Singapore Market Roundup (22-Jul-2026): CGS International boosts Yangzijiang target price to

CGS International raises Yangzijiang Shipbuilding’s target price to $5.10.
RHB maintains positive outlook on CLAR, expecting DPU rise from FY2027.
UOBKH reiterates ‘buy’ on Riverstone, focusing on ASP normalisation and returns.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 22

0

Daily Brief Thematic (Sector/Industry): Japan Morning Connection: SPE and Memory Rebound Set to Build After Strong US Follow Through and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Japan Morning Connection: SPE and Memory Rebound Set to Build After Strong US Follow Through
Exencial Industry Tidings – 21-07-2026

Japan Morning Connection: SPE and Memory Rebound Set to Build After Strong US Follow Through

MTD laggards may draw continued dip buying. Kioxia remains -32% since the start of the quarter despite yesterday’s rebound.
Optical/Photonics caught a bid overnight, so expect interest in the likes of QD Laser, Santec, Samco and Seiko Giken.
Expect moves up for JP Space names after Sidus +17.1%, AST +10.3%, though SpaceX’s August 6 lock-up expiry could weigh on sentiment into next month.

Exencial Industry Tidings – 21-07-2026

By Viral Kishorchandra Shah

IVPA urges govt for policy review as refined edible oil imports from Nepal surge
Onion farmers urge govt to develop Nashik as National Onion Export Hub
Himalaya NITI Abhiyan asks Himachal Pradesh govt to stop sale of hazardous pesticides

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 21

0

Daily Brief Thematic (Sector/Industry): Japan Morning Connection: AI Setup Remains Tepid but Kioxia May Catch a Bid with CXMT Oversubscribed and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Japan Morning Connection: AI Setup Remains Tepid but Kioxia May Catch a Bid with CXMT Oversubscribed
India Data Center Monthly: Geopolitics, Gujarat’s 7.5 GW Bid, and a Capex Supercycle Taking Shape
ALMM-II Extension: Six Months Setback for Waaree & Premier Energies
Buffet’s Berkshire: Passing the Torch = The Legacy Continues + Donating It ALL!
Exencial Industry Tidings – 20-07-2026

Japan Morning Connection: AI Setup Remains Tepid but Kioxia May Catch a Bid with CXMT Oversubscribed

QD Laser and other optical names may see a small lift after Barclays upgraded Lumentum to overweight on the optical hardware outlook.
TEL, Lasertec and Screen worth watching this week ahead of Intel earnings, with capex spending expected to come in above estimates.
Kioxia may catch a bid ahead of CXMT’s listing on July 27, with the institutional tranche reportedly 570x oversubscribed.

India Data Center Monthly: Geopolitics, Gujarat’s 7.5 GW Bid, and a Capex Supercycle Taking Shape

By Garvit Bhandari

Middle East data center strikes in March 2026 are re-routing Gulf workloads to India. Gujarat’s new policy targets US$62.9bn in investments and 7.5 GW of capacity.
Capital inflows are accelerating: CPP committed US$741 million to CtrlS, Amazon raised its India commitment to US$48 billion, and H1 2026 foreign investment reached US$738 million.
Demand is projected to grow from 1.3 GW (FY25) to 4.7-5.7 GW by FY30, a 30-35% CAGR. We see a multi-year structural upcycle with power as the binding constraint.

ALMM-II Extension: Six Months Setback for Waaree & Premier Energies

By Sudarshan Bhandari

Net-Metering and open-access projects can commission without ALMM-II-compliant domestic cells until 31 December 2026, versus 31 May earlier.
The extension delays the demand and pricing advantage expected by integrated cell manufacturers just as major domestic capacities are ramping up.
Near-Term earnings risk rises for Waaree and Premier; CleanMax gains procurement flexibility, lower capex risk and improved execution certainty.

Buffet’s Berkshire: Passing the Torch = The Legacy Continues + Donating It ALL!

By Maverick Equity Research

As a quick preview, I expect 1-3 surprises in the 2nd quarter. One of them is regarding Berkshire accelerating the stock buybacks!
after digging into the various Berkshire fillings, together with Buffett’s own annual charitable giving July disclosures, based on various sleek calculations, there is a high probability (not a guarantee) of way more stock buybacks in Q2
should that be the case, I expect the media and pundits to wake up, and the stock to react once the results are out — that is because it would mean the stock is trading below the Intrinsic Value

Exencial Industry Tidings – 20-07-2026

By Viral Kishorchandra Shah

Textile exports need stronger manufacturing to benefit from China+1: 360 One Capital
Textile exports need stronger manufacturing to benefit from China+1: 360 One Capital
Project completions in electricity generation industry rise to Rs.535.7 billion in June 2026 quarter

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 20

0

Daily Brief Thematic (Sector/Industry): This Week in AI (Jul 12-18): Grok 4.5 and Kimi K3; Zhipu Hits $1bn ARR as Anthropic Readies IPO and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

This Week in AI (Jul 12-18): Grok 4.5 and Kimi K3; Zhipu Hits $1bn ARR as Anthropic Readies IPO
Ohayo Japan | Tech Sell-Off Drags US Stocks Lower Ahead of Mag-7 Earnings
China Healthcare Weekly Wrap (13-17 July)
SEMICONDUCTOR MEMORY CYCLE MONITOR — Issue #2 | 28 June – 17 July 2026

This Week in AI (Jul 12-18): Grok 4.5 and Kimi K3; Zhipu Hits $1bn ARR as Anthropic Readies IPO

By Ke Yan, CFA, FRM

We tracked AI models, infrastructure and M&A this week, led by Kimi K3, Grok 4.5 and new financing plans from DeepSeek.
China approved Apple Intelligence, while Zhipu expanded sales and Tencent released smaller Hunyuan Hy3 variants.
Anthropic prepared for an IPO, TSMC raised capital spending, and Databricks, Helsing and Fireworks AI announced new funding.

Ohayo Japan | Tech Sell-Off Drags US Stocks Lower Ahead of Mag-7 Earnings

Nasdaq -1.4% as AI/semiconductor stocks extended their sell-off ahead of Mag-7 earnings.
Middle East tensions escalated, lifting oil and supporting energy stocks.
China’s Kimi K3 AI model renewed concerns over US AI leadership, adding pressure to AI- linked names

China Healthcare Weekly Wrap (13-17 July)

By Wilfred Yuen

BD&L deal flows continue: 1) Dizal/AstraZeneca on EGFR inhibitor Zegfrovy, 2) Innovent/Spero on CD40L, 3) Insilico Medicine/Bora on AI drug discovery, 4) Hansoh/Avere on oral IL23
Pharmaron and Joinn Lab provided 1H26 results previews. Hengrui’s NewCo Braveheart files for IPO. Legend’s Carvykti generated sales of USD657m (+49% YoY or +10% QoQ) in 2Q26.
China’s outbound drug licensing deal value reached c.USD110bn in 1H26, setting another new historic high, per NMPA. Moreover, China approved 38 Class I new drug in 1H26.

SEMICONDUCTOR MEMORY CYCLE MONITOR — Issue #2 | 28 June – 17 July 2026

By Mo Aziz

Memory stocks fell 28% month-to-date in July. Korea’s KOSPI hit its third-worst session since Lehman. 1.2 million leveraged retail accounts were margin-called. Leverage unwinding, not a demand signal.
SK Hynix’s ADR (SKHY) priced at USD149 — seven times oversubscribed, the largest US share sale ever by a foreign company — before the same retail book got margin-called.
Long SK Hynix (000660 KS / SKHY US): 56% HBM share, 72% operating margin, ~7x forward earnings. Catalyst: Q2 results 29 July. Alternative: Long DRAM US ETF (US$52.72, target US$74).

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 19

0

Daily Brief Thematic (Sector/Industry): Shougang LanzaTech: Beyond Ethanol Toward Industrial Process Technology and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Shougang LanzaTech: Beyond Ethanol Toward Industrial Process Technology
REF China Property Developers In Distress – Weekly News & Announcements Tracker | July 10-16, 2026
APAC Healthcare Weekly (July 19) – Kelun Bio, CSPC Pharma, Insilico, Eisai, Celltrion, Mesoblast

Shougang LanzaTech: Beyond Ethanol Toward Industrial Process Technology

By Duncan Chan

The market values Beijing Shougang Lanzatech Technology (2553 HK) primarily as a low-carbon ethanol producer, underestimating its transition toward an industrial carbon-conversion platform driven by technology, engineering and licensing.
Four commercial plants have proven gas fermentation at industrial scale. Near-term losses keep focus on whether technology licensing and integrated solutions can deliver recurring, higher-quality earnings beyond manufacturing.
We remain constructive. Our bear, base and bull cases imply valuations of HK$20–22, HK$30–33 and HK$40+, respectively, depending on utilisation, technology licensing and integrated solutions becoming meaningful earnings drivers.

REF China Property Developers In Distress – Weekly News & Announcements Tracker | July 10-16, 2026

By Robert Ciemniak

This note is a weekly (select weeks on SK) curated selection of Chinese news articles and company announcements focused on developers in distress
We look for their deals, updates, specific project progress news (‘local signals’), as well as relevant local research commentaries about the market
We do not verify the underlying data or provide any opinion; we only select and summarise the information. See direct links to the sources

APAC Healthcare Weekly (July 19) – Kelun Bio, CSPC Pharma, Insilico, Eisai, Celltrion, Mesoblast

By Tina Banerjee

Sichuan Kelub Biotech’s sac-TMT in combination with Keytruda as a first-line treatment for PD-L1-negative non-squamous NSCL) met primary endpoint. NMPA accepted CSPC Pharma’s NDA for Trastuzumab Envedotin (HER2-targeted ADC).
InSilico Medicine announced a multi-target strategic alliance with Bora Pharmaceuticals. Eisai secured FDA approval for a once-weekly Leqembi subcutaneous autoinjector as an initiation dose for Alzheimer’s disease.
Celltrion obtained domestic approval for Phase 1 clinical trials for its Tremfya biosimilar candidate, CT-P68. Mesoblast achieved target of 300 patients treated in Phase 3 trial of rexlemestrocel-L for CLBP.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars

Jul 18

0

Daily Brief Thematic (Sector/Industry): Singapore Market Roundup (17-Jul-2026): Maybank sees optimism in Addvalue’s share buybacks. and more

By Smartkarma Daily Briefs | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

Singapore Market Roundup (17-Jul-2026): Maybank sees optimism in Addvalue’s share buybacks.
Asia Real Estate Tracker (17-Jul-2026): UniSuper, IFM secure $698M Sydney Logistics Park.
Japan Strategy Weekly | After the Bubble
AUCTUS ON FRIDAY – 17.07.2026
India Semiconductor Mission 2.0: Strengthening India’s Position in the Global Chip Value Chain

Singapore Market Roundup (17-Jul-2026): Maybank sees optimism in Addvalue’s share buybacks.

Addvalue’s share buybacks signal optimism, says Maybank on ‘re-boarding’ chance.
DBS: ComfortDelGro’s recent bus package loss is ‘immaterial’ to earnings.
RHB maintains ‘buy’ rating for Marco Polo Marine with a 21 cents target.

Asia Real Estate Tracker (17-Jul-2026): UniSuper, IFM secure $698M Sydney Logistics Park.

UniSuper and IFM have secured approval for a significant $698 million logistics park in Sydney.
Weave has expanded its portfolio with a second acquisition in Australia’s student housing market.
CapitaLand Ascendas REIT has divested a data center in Singapore for $155 million in recent activity.

Japan Strategy Weekly | After the Bubble

The AI bubble has probably burst. The evidence points not to a dramatic collapse but a gradual deflation, with speculative semiconductor names leading declines while market leaders remain resilient.
History suggests the unwind is incomplete. Bubble collapses become dangerous only when leverage meets a funding shock. For now, watch the yen carry trade, margin debt and AI capex.
Yaskawa showed execution matters as much as demand. Orders surged, but an ERP implementation crippled production and margins—a reminder that software can indeed eat the world

AUCTUS ON FRIDAY – 17.07.2026

By Auctus Advisors

AUCTUS PUBLICATIONS ________________________________________ CanCambria Energy (CCEC CN)C; Target price of C$3.00 per share: Framing the Soltvadkert shallow play – CanCambria has released additional information on the Soltvadkert shallow play, where the acquisition of modern 3D seismic is scheduled to commence in 3Q26.
Ten oil prospects have been mapped using 1980s‑vintage 2D seismic across an 80,000‑acre fairway, adjacent to legacy fields that have collectively produced ~160 mmboe.
The area was drilled extensively during the 1960s–1980s, with ~400 legacy wells on CCEC acreage.

India Semiconductor Mission 2.0: Strengthening India’s Position in the Global Chip Value Chain

By Sudarshan Bhandari

India Semiconductor Mission 2.0 expands policy support to INR 1,27,500 crore across six pillars, building on 12 approved units and over INR 1.64 lakh crore of Phase-I investment.
India is moving beyond subsidy-led fabs toward design IP, equipment, materials, advanced packaging, R&D and talent- critical for reducing imports and creating a durable semiconductor cluster.
Semicon 2.0 is structurally positive, but commercial production, customer qualification, localisation, talent, subsidy disbursement and utilisation will decide which companies convert policy support into durable earnings.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

✓ Unlimited Research Summaries
✓ Personalised Alerts
✓ Custom Watchlists
✓ Company Data and News
✓ Events & Webinars